Targeted protein degradation (TPD) has become one of the most promising approaches in modern drug discovery, with proteolysis-targeting chimeras (PROTACs) at the forefront. Rather than simply inhibiting disease-causing proteins, PROTACs harness the cell's natural protein disposal machinery to selectively eliminate them, creating new opportunities to address targets that have traditionally been considered undruggable.
Image Credit: Bruker BioSpin
Designing effective PROTACs, however, remains a complex challenge. Success depends on identifying ligands that bind both the target protein and an E3 ligase, engineering a linker that promotes productive interactions, and ensuring the resulting ternary complex remains stable long enough to trigger ubiquitination and degradation. Because these large, multifunctional molecules often face challenges such as poor permeability and limited bioavailability, researchers are increasingly adopting integrated characterization strategies throughout the development process.
A recent application note from Novalix and Bruker highlights how combining complementary biophysical techniques with cellular validation can help streamline PROTAC development. Using the cancer-relevant protein BRD4 and the E3 ligase cereblon (CRBN) as a model system, the researchers established a workflow that tracks PROTAC candidates from ligand discovery through confirmation of cellular protein degradation.
The workflow begins with DNA-encoded library (DEL) screening, allowing researchers to rapidly identify selective BRD4 binders from millions of small molecules. These ligands provide the starting point for PROTAC design, with their defined attachment sites simplifying conjugation to an E3 ligase-recruiting moiety.
After candidate molecules have been synthesized, biophysical techniques provide a detailed understanding of their performance. Surface plasmon resonance (SPR) is used to quantify binary binding kinetics and evaluate selectivity across different BRD4 constructs, helping researchers assess how linker design influences target engagement. Meanwhile, switchSENSE® technology and a Y-structure proximity assay enable direct analysis of ternary complex formation, revealing how cooperativity, binding dynamics, and complex stability contribute to productive protein degradation.
These molecular measurements are complemented by cellular assays that determine whether the observed interactions translate into biological activity. The biophysical data correlated with cellular evidence of BRD4 ubiquitination and degradation, demonstrating that the characterized ternary complexes successfully triggered the intended mechanism within cells.
In addition to measuring ternary complex kinetics, switchSENSE® can detect PROTAC-induced conformational changes in the target protein, providing insight into structural effects that may either promote or hinder productive target-ligase assembly. In the reported study, a short-linker PROTAC induced a pronounced conformational compaction of BRD4 that was associated with destabilized ternary complex formation and loss of degradation activity, highlighting the importance of protein conformation in degrader design.
By integrating ligand discovery, kinetic characterization, ternary complex analysis, conformational profiling and cellular validation into a unified workflow, researchers can develop a more complete understanding of PROTAC behavior. This data-driven strategy not only increases confidence in candidate selection but also provides valuable mechanistic insights that support the optimization of next-generation targeted protein degraders.
About Bruker BioSpin Group
The Bruker BioSpin Group designs, manufactures, and distributes advanced scientific instruments based on magnetic resonance and preclinical imaging technologies. These include our industry-leading NMR and EPR spectrometers, as well as imaging systems utilizing MRI, PET, SPECT, CT, Optical and MPI modalities. The Group also offers integrated software solutions and automation tools to support digital transformation across research and quality control environments.
Bruker BioSpin’s customers in academic, government, industrial, and pharmaceutical sectors rely on these technologies to gain detailed insights into molecular structure, dynamics, and interactions. Our solutions play a key role in structural biology, drug discovery, disease research, metabolomics, and advanced materials analysis. Recent investments in lab automation, optical imaging, and contract research services further strengthen our ability to support evolving customer needs and enable scientific innovation.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.net, which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.